Antares Pharma (ATRS) Reports In-Line Q2 Loss
Tweet
Share
E-mailGet Alerts ATRS Hot Sheet
Join SI Premium – FREE
Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.43 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
- KULR Technology Group (KULR) Misses Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
